Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.
By M. Audeh, J. Carmichael, R. Penson, M. Friedlander, B. Powell, K. Bell-McGuinn, C. Scott, J. Weitzel, A. Oaknin, N. Loman and 5 more. The Lancet, 2010
1,894 citations recorded by the source corpus.
Subfields: Genetics, Oncology, Reproductive Medicine
View Paper: https://www.semanticscholar.org/paper/fd96a283dfa12c8fe3e67d593269828234283cb5
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
In Oncology
In Reproductive Medicine
Citations in the corpus
- The histone methyltransferase SMYD2 methylates PARP1 and promotes poly(ADP-ribosyl)ation activity in cancer cells. (2014, background): “As a novel class of anticancer drugs, more than 40 preclinical studies or clinical trials of PARP inhibitors are ongoing [39,41-44].”
- Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. (2017, background): “harbouring a germline BRCA mutation, 6% a somatic BRCA mutation, and 20% a mutation in, or epigenetic silencing of, another homologous recombination gene.(7,8) Even without an identifiable BRCA or other known homologous recombination gene mutation, many high-grade serous ovarian carcinomas display B”
- Molecular Pathogenesis and Extraovarian Origin of Epithelial Ovarian Cancer. Shifting the Paradigm (2011, positive): “It is therefore likely that poly(ADP-ribose) polymerase inhibitors will be effective in treating sporadic and hereditary ovarian type II carcinomas as a monotherapy or in combination with other cytotoxic reagents [91-94].”